U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07481669) titled 'ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse' on March 15.
Brief Summary: In the era of novel therapeutic agents, high-dose conditioning chemotherapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT) remains an important and feasible consolidation strategy for non-Hodgkin lymphoma, especially for high-risk and relapsed/refractory patients. It can effectively prolong progression-free survival and even overall survival in chemotherapy-sensitive lymphoma patients, and its application in domestic clinical practice has become increasingly widespread.
With long-term and extensive use ...